Varian, a Siemens Healthineers company, has received 510(k) approval from the US Food and Drug Administration (FDA) for its IntelliBlate microwave ablation system.
The system, designed for the ablation of soft tissue, aims to enhance procedural predictability, precision, and control for clinicians.
According to Varian, IntelliBlate will support the future-focused, integrated ecosystem for microwave ablation.
IntelliBlate generates large, controlled spherical ablation zones for reliable treatment delivery.
It offers the flexibility of using either single or dual probes, which can be operated with linked or independent controls, catering to the unique needs of each patient.
The Ximitry probe enhances precision and control with features like Laser Disk Alignment and LED indicators.
Designed to be compact and versatile, IntelliBlate boasts a user-friendly interface and portability, making it a flexible solution for this treatment method.
Its modular components allow clinicians to expand their treatment capabilities as clinical demands evolve while maintaining operational efficiency.
Varian Interventional Solutions vice president and chief medical officer David Hahn said: “IntelliBlate combines the features our customers say are most important for an efficient, integrated solution to seek improved levels of performance in microwave ablation.
“This innovative system brings new versatility in treatment options, fuelling clinician-driven innovation to tackle a wide variety of cases.
“Real-time monitoring and treatment information at the tissue level aims to further empower care teams with the confidence to deliver highly personalised care to patients.”
The Siemens Healthineers company plans to integrate advanced therapeutic technologies and image-guided innovations into a unified platform.
The upgrade will further enhance clinicians’ ability to predict probe placement, optimise treatment delivery, and confirm procedural outcomes with more accuracy.
IntelliBlate solution shows Varian’s dedication to advancing interventional solutions through investment in advanced technology.
Varian was acquired by Siemens Healthineers in August 2020 for $16.4bn.
Recently, the company secured 510(k) clearance from the US FDA for new functionality to its Ethos therapy system.
